Kymera Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 285

Employees

  • Stock Symbol
  • KYMR

Stock Symbol

  • Share Price
  • $115.01
  • (As of Friday Closing)

Kymera Therapeutics General Information

Description

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 500 North Beacon Street
  • 4th Floor
  • Watertown, MA 02472
  • United States
+1 (857)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 500 North Beacon Street
  • 4th Floor
  • Watertown, MA 02472
  • United States
+1 (857)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kymera Therapeutics Stock Performance

As of 20-Nov-2026, Kymera Therapeutics’s stock price is $115.01. Its current market cap is $9.8B with 85.4M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$115.01 $119.39 $63.69 - $142.92 $9.8B 85.4M 847K -$3.63

Kymera Therapeutics Financials Summary

As of 30-Sep-2026, Kymera Therapeutics has a trailing 12-month revenue of $102M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 8,682,981 5,803,039 2,143,768 1,135,727
Revenue 102,235 39,211 47,072 78,592
EBITDA (396,783) (341,086) (254,262) (161,965)
Net Income (349,425) (311,351) (223,858) (146,962)
Total Assets 1,767,269 1,742,812 978,035 575,759
Total Debt 76,599 82,252 87,761 84,674
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kymera Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kymera Therapeutics‘s full profile, request access.

Request a free trial

Kymera Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Kymera Therapeutics‘s full profile, request access.

Request a free trial

Kymera Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human di
Drug Discovery
Watertown, MA
285 As of 2026

Watertown, MA
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kymera Therapeutics Competitors (33)

One of Kymera Therapeutics’s 33 competitors is Foghorn Therapeutics, a Formerly VC-backed company based in Watertown, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Foghorn Therapeutics Formerly VC-backed Watertown, MA
Nurix Therapeutics Formerly VC-backed San Francisco, CA
Cullgen Formerly VC-backed San Diego, CA
Vividion Therapeutics Formerly VC-backed San Diego, CA
Arvinas Formerly VC-backed New Haven, CT
You’re viewing 5 of 33 competitors. Get the full list »

Kymera Therapeutics Patents

Kymera Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026236697-A1 Irf5 degraders and uses thereof Pending 08-May-2025
WO-2026236688-A1 Irf5 inhibitors and uses thereof Pending 08-May-2025
WO-2026196156-A1 Cyclin-dependent kinase 2 (cdk2) molecular glue degraders Pending 17-Mar-2025
WO-2026188211-A1 Stat6 degraders and uses thereof Pending 06-Mar-2025
WO-2026188071-A1 Stat6 degraders and uses thereof Pending 05-Mar-2025 C07D471/04
To view Kymera Therapeutics’s complete patent history, request access »

Kymera Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kymera Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

22.05 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Kymera Therapeutics’s complete esg history, request access »

Kymera Therapeutics FAQs

  • When was Kymera Therapeutics founded?

    Kymera Therapeutics was founded in 2015.

  • Where is Kymera Therapeutics headquartered?

    Kymera Therapeutics is headquartered in Watertown, MA.

  • What is the size of Kymera Therapeutics?

    Kymera Therapeutics has 285 total employees.

  • What industry is Kymera Therapeutics in?

    Kymera Therapeutics’s primary industry is Drug Discovery.

  • Is Kymera Therapeutics a private or public company?

    Kymera Therapeutics is a Public company.

  • What is Kymera Therapeutics’s stock symbol?

    The ticker symbol for Kymera Therapeutics is KYMR.

  • What is the current stock price of Kymera Therapeutics?

    As of 20-Nov-2026 the stock price of Kymera Therapeutics is $115.01.

  • What is the current market cap of Kymera Therapeutics?

    The current market capitalization of Kymera Therapeutics is $9.8B.

  • What is Kymera Therapeutics’s current revenue?

    The trailing twelve month revenue for Kymera Therapeutics is $102M.

  • Who are Kymera Therapeutics’s competitors?

    Foghorn Therapeutics, Nurix Therapeutics, Cullgen, Vividion Therapeutics, and Arvinas are some of the 33 competitors of Kymera Therapeutics.

  • What is Kymera Therapeutics’s annual earnings per share (EPS)?

    Kymera Therapeutics’s EPS for 12 months was -$3.63.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process